Mirabegron

• The Food and Drug Administration staff said the once-daily tablet, called mirabegron, worked to reduce frequent urination and the inability to control it, according to documents released online on Tuesday.
(msnbc.com)
• WASHINGTON, April 3 (Reuters) - U.S. drugs reviewers said Astellas Pharma Incs treatment for an overactive bladder worked, but raised concerns about liver and heart safety issues. The U.S.
(Huffington Post)
• The risks were included in a Food and Drug Administration report released today ahead of an April 5 meeting of FDA advisers on the drug, known as mirabegron. To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.
(Bloomberg)
• The first event on the docket is an Advisory Committee meeting for Astellas Pharmas (ALPMY.PK) Mirabegron. Mirabegron is a once daily beta three receptor intended to treat patients with overactive bladder (OAB).
(Seekingalpha.com)
• On Thursday, the FDAs Reproductive Health Drugs Advisory Committee will discuss the benefits and risks of beta-3-adrenoceptor (AR) agonist mirabegron to treat overactive bladder.
(MedPage Today)